3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
19
NIH
2
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
CNS
14
Thoracic
3
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2550
Triple Negative Breast Neoplasms
435
Carcinoma, Non-Small-Cell Lung
338
Ovarian Neoplasms
315
Neoplasms
280
Neoplasm Metastasis
253
Colorectal Neoplasms
245
Stomach Neoplasms
202
Pancreatic Neoplasms
196
Prostatic Neoplasms
188
Lung Neoplasms
180
Melanoma
171
Squamous Cell Carcinoma of Head and Neck
140
Endometrial Neoplasms
140
Head and Neck Neoplasms
124
Carcinoma, Renal Cell
118
Uterine Cervical Neoplasms
104
Esophageal Neoplasms
97
Urinary Bladder Neoplasms
92
Small Cell Lung Carcinoma
87
Sarcoma
84
Colonic Neoplasms
80
Carcinoma, Hepatocellular
62
Carcinoma, Transitional Cell
61
Kidney Neoplasms
51
Advanced Breast Cancer
51
Cholangiocarcinoma
50
Liver Neoplasms
47
Brain Neoplasms
43
Mesothelioma
37
Interventions
paclitaxel-Angiopep-2 conjugate
1
eribulin
1
Methotrexate
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Meningeal Carcinomatosis
×
Breast
×
Clear all
NCT05414123
2023-10-16
FORESEE
Biocept, Inc.
Terminated
40 enrolled
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled